Volition announces Mayo Clinic study results

VolitionRx Limited has announced the publication of a new clinical study from the Mayo Clinic demonstrating elevated Nu.Q® concentrations in trauma patients. This finding suggests the potential utility of Volition's biomarker technology in assessing trauma severity or patient outcomes. The epigenetics company's research continues to explore the diagnostic and prognostic value of its tests.